Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Active not recruiting 2Suspended 1Recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Dermatologic 1

Conditions

Lymphoma, Follicular 10Sarcoma 6Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell 4Rhabdoid Tumor 3Prostatic Neoplasms 3Wilms Tumor 2Sarcoma, Synovial 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Tertiary Lymphoid Structures 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1

Interventions

Cyclophosphamide 49Rituximab 32fludarabine 30Doxorubicin 14Specimen Handling 13Magnetic Resonance Spectroscopy 13Vincristine 12Prednisone 12fludarabine phosphate 11pirtobrutinib 10Etoposide 10Bendamustine Hydrochloride 10obinutuzumab 8Lenalidomide 8Immunotherapy, Adoptive 8Biopsy 8venetoclax 7polatuzumab vedotin 7pembrolizumab 7glofitamab 7zanubrutinib 6Dexamethasone 6tafasitamab 5ibrutinib 5etoposide phosphate 5acalabrutinib 5Leukapheresis 5tazemetostat 4loncastuximab tesirine 4Nivolumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × tazemetostat × 1 year × Clear all
NCT05627245 2026-05-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

National Cancer Institute (NCI)

Phase 1 Active not recruiting
48 enrolled
DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT06242834 2026-05-07

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Northwestern University

Phase 2 Active not recruiting
32 enrolled
Lymphoid

Lymphoma, B-Cell

NCT06824701 2026-04-06

TARZAN

University of Utah

Phase 1 Suspended
24 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

NCT05934838 2025-08-15

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Weill Medical College of Cornell University

Phase 1 Recruiting
15 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡